Aptevo Therapeutics Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $3.1M | $12.3M |
| Operating income | -$26.3M | -$24.6M | -$28.9M | -$28.6M | -$21.4M |
| Cash from operations | -$25.6M | -$23.8M | -$11.7M | -$21.0M | -$21.7M |
| Capital expenditure | — | — | — | $29,000 | $713,000 |
| Free cash flow | — | — | — | -$21.1M | -$22.4M |
| Total assets | $27.2M | $15.6M | $24.8M | $34.2M | $56.6M |
| Total liabilities | $9.8M | $10.8M | $12.6M | $16.2M | $55.4M |
Shares outstanding 1.2M · Free float 91.0%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.